Keytruda Receives Triple-Negative Breast Cancer Indication
The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) in combination with chemo-therapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express programmed death ligand-1 (PD-L1; combined positive score [CPS] ≥10), as determined by an FDA-approved test.